Cargando…

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3

Gastroenteropancreatic neuroendocrine neoplasms grade 3 (GEP-NENs G3) are rare tumors. These highly aggressive neoplasms are traditionally treated with platinum-based chemotherapy in combination with etoposide. Immune checkpoint proteins such as programmed cell death ligand (PD-L1) may have a role i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Abir Salwa, Langer, Seppo W., Federspiel, Birgitte, Hjortland, Geir Olav, Grønbæk, Henning, Ladekarl, Morten, Welin, Staffan, Weber Vestermark, Lene, Arola, Johanna, Osterlund, Pia, Knigge, Ulrich, Sørbye, Halfdan, Micke, Patrick, Grimelius, Lars, Grönberg, Malin, Tiensuu Janson, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735636/ https://www.ncbi.nlm.nih.gov/pubmed/33315908 http://dx.doi.org/10.1371/journal.pone.0243900

Ejemplares similares

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma
por: Ali, Abir Salwa, et al.
Publicado: (2017)

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
por: Ali, Abir Salwa, et al.
Publicado: (2018)

Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3
por: Ali, Abir Salwa, et al.
Publicado: (2020)

Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort
por: Papantoniou, Dimitrios, et al.
Publicado: (2023)

Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review
por: Ilett, Emma Elizabeth, et al.
Publicado: (2015)

A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors
por: Dumanski, Jan P, et al.
Publicado: (2017)

The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
por: Venizelos, Andreas, et al.
Publicado: (2021)

P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms
por: Nielsen, Kirstine, et al.
Publicado: (2020)

Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors
por: Thiis‐Evensen, Espen, et al.
Publicado: (2022)

Volumetric parameters from [ (18)F]FDG PET/CT predicts survival in patients with high‐grade gastroenteropancreatic neuroendocrine neoplasms
por: Langen Stokmo, Henning, et al.
Publicado: (2022)

Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma
por: Knappskog, Stian, et al.
Publicado: (2023)

Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma
por: Mollazadegan, Kazhan, et al.
Publicado: (2021)

Multiple hormone secretion may indicate worse prognosis in patients with ectopic Cushing’s syndrome
por: Lase, Ieva, et al.
Publicado: (2020)

Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2
por: Papantoniou, Dimitrios, et al.
Publicado: (2020)

Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 83 Patients
por: Olsen, Ingrid Holst, et al.
Publicado: (2015)

Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas
por: Dasari, Arvind, et al.
Publicado: (2022)

Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation
por: Binderup, Tina, et al.
Publicado: (2013)

Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas
por: Olsen, Ingrid Holst, et al.
Publicado: (2014)

Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
por: Olsen, Ingrid H., et al.
Publicado: (2012)

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
por: Winther, Stine Braendegaard, et al.
Publicado: (2017)

Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era
por: Rodriguez-Freixinos, Víctor, et al.
Publicado: (2021)

A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for (68)Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
por: Virgolini, Irene, et al.
Publicado: (2022)

Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases
por: Langer, Seppo W., et al.
Publicado: (2015)

Ghrelin is a prognostic marker and a potential therapeutic target in breast cancer
por: Grönberg, Malin, et al.
Publicado: (2017)

Incidence, Clinical Presentation and Trends in Indication for Diagnostic Work-Up of Small Intestinal and Pancreatic Neuroendocrine Tumors
por: Stensbøl, Anna Bryan, et al.
Publicado: (2021)

Melatonin Immunoreactivity in Malignant Small Intestinal Neuroendocrine Tumours
por: Söderquist, Fanny, et al.
Publicado: (2016)

Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors
por: Baekdal, Jonas, et al.
Publicado: (2020)

Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases
por: Angelsen, Jon-Helge, et al.
Publicado: (2015)

Clinical features of gastroenteropancreatic tumours
por: Gut, Paweł, et al.
Publicado: (2015)

Ghrelin expression is associated with a favorable outcome in male breast cancer
por: Grönberg, Malin, et al.
Publicado: (2018)

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors
por: Kunz, Pamela L, et al.
Publicado: (2010)

Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment
por: Díez, Marc, et al.
Publicado: (2013)

Endoscopic Ultrasound in Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Michelle Kang
Publicado: (2012)

Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
por: Rinke, Anja, et al.
Publicado: (2012)

Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Mafficini, Andrea, et al.
Publicado: (2019)

Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias
por: Sharma, Rohini, et al.
Publicado: (2021)

An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
por: Fang, Jiayun M, et al.
Publicado: (2022)

Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors
por: Crabtree, Judy S.
Publicado: (2022)

Advances in the imaging of gastroenteropancreatic neuroendocrine neoplasms
por: Ramachandran, Anupama, et al.
Publicado: (2022)

Mechanisms of Resistance in Gastroenteropancreatic Neuroendocrine Tumors
por: Shi, Chanjuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4r8h8ie59p0lsbcc7fp70j7fuj